课题基金 / 基金详情

FOLLOW-UP INTRAOCULAR PRESSURE AND THE RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAU

FOLLOW-UP INTRAOCULAR PRESSURE AND THE RISK OF DEVELOPING PRIMARY OPEN-ANGLE GLAU
后续眼内压和发生原发性开角型青光眼的风险
批准号:
7738234
负责人:
MAE O GORDON
金额:
$19.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2011-07-31

项目摘要

项目成果

MAE O GORDON的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): As many as 10 million Americans over the age of 40 years are at risk for developing glaucoma because of ocular hypertension, but only 2.4 million of these 10 million are estimated to have a >2% annual risk of developing POAG and thus meet the cost-effectiveness threshold to initiating hypotensive treatment. The challenge is to identify the 25% of the "at risk" individuals for whom treatment is indicated from the 75% for whom treatment is not cost-effective. Our prediction model which calculates the 5-year risk of developing primary open angle glaucoma (POAG) in individuals with ocular hypertension is based on the pooled data of the untreated arms (n=1,319 participants) of the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS). This prediction model is available on our interactive "risk calculator" web site which has attracted more than 8,000 unique visitors from 72 countries in less than a year. We would like to increase the predictive accuracy and clinical utility of this risk calculator. No prediction model to date, including ours, gives clinicians and patients evidence-based guidance on the reduction of glaucoma risk at various target IOPs (in mmHg) adjusted for the patient's baseline risk factors (Aim 1). The Specific Aims of the proposed study are: Aim 1. To determine the impact of IOP reduction on the risk of developing POAG. We will also determine whether adjusting IOP for CCT increases the precision of the prediction model for development of POAG. Aim 2. To identify baseline factors associated with follow-up IOP (treated and untreated) in ocular hypertensive individuals. Aim 3. To determine if the predictive accuracy of the existing OHTS/EGPS baseline prediction model for the development of POAG is increased by including information on follow-up IOP level, trend or variability. Translation of research findings into clinical practice will be accelerated by placing a link or PDF copy of publications on our website and by including the calculation of target treatment IOPs on the web-based interactive risk calculator. The analysis dataset will include both treated and untreated groups in OHTS and EGPS, a total of N=2,614 participants with a median follow-up of 5.5 years and 260 cases of POAG. The datasets have already been de-identified and harmonized so that the proposed analyses can be undertaken. The Steering Committees of the OHTS and EGPS have approved the collaborative analyses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Long-Term Quality of Life in the Ocular Hypertension Treatment Study Cohort
  • 批准号:
    10667711
  • 项目类别:
  • 资助金额:
    $24.63万
  • 财政年份:
    2023
  • 负责人:
    MAE O GORDON
  • 依托单位:
Resubmission: Latent Class Trajectory Analysis in the OHTS Study
  • 批准号:
    10675764
  • 项目类别:
  • 资助金额:
    $23.33万
  • 财政年份:
    2022
  • 负责人:
    MAE O GORDON
  • 依托单位:
Resubmission: Latent Class Trajectory Analysis in the OHTS Study
  • 批准号:
    10540153
  • 项目类别:
  • 资助金额:
    $19.65万
  • 财政年份:
    2022
  • 负责人:
    MAE O GORDON
  • 依托单位:
Innovative Analytical Methods for Repeated Measures in the OHTS Study
  • 批准号:
    10219276
  • 项目类别:
  • 资助金额:
    $23.59万
  • 财政年份:
    2020
  • 负责人:
    MAE O GORDON
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: